RecruitingPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

United States232 participantsStarted 2024-10-24

Plain-language summary

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m.

Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

Timeframe: Baseline to Day 35

Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR)

Timeframe: Baseline to Week 24

Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

Timeframe: From Day 1 until Week 106

NCT IDNCT06649110

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-11-29

Novartis Pharmaceuticals